Human platelet lysate: from discard to value products in cell therapy and advanced cell-based medicine

• Grant number: 16/14459-3
• Support type: Research Grants - Innovative Research in Small Business - PIPE
• Duration: June 01, 2017 - February 28, 2018
• Field of knowledge: Biological Sciences - Biology
• Principal Investigator: Sheila Siqueira Andrade
• Grantee: Sheila Siqueira Andrade
• Company: Plateinnove Biotechnology Pesquisas Ltda
• City: Piracicaba
• Assoc. researchers: Manoel João Batista Castello Girão
• Associated grant(s): 17/26317-1 - InGrowth, biomimetic product developed by platelet bioactivation platform: applications in the veterinary and research and development areas, AP.PIPE
• Associated scholarship(s): 17/10761-0 - Human platelet lysate: from discard to value products in cell therapy and advancing cell based medicine, BP.PIPE

Abstract

In a scenario in which cell biotechnology emerges in the direction of regenerative medicine, the development of cell supplementation products that are both devoid of xenogeneic proteins and effective in promoting cell growth is of great value. Although still almost intangible, several initiatives around the world aim to capture this high-value market where one liter of human platelet lysate (HPL) costs over US$ 4,000 (Merck Millipore Corporation, 2016). Aware of this challenge, we academically described the potential use of platelets rich plasma (PRP) and HPL as promising substitutes for the classic fetal bovine serum (FBS) in mammalian cells culture [1,2]. Supported and encouraged by the obtained results, our efforts are now concentrated on biomimetic research mainly focusing on the development of production technologies and their respective supplementation products derived from cell platelets in their various aspects. Briefly, we will use our know-how of the following techniques: i) washed and activated platelets through specific agonists to obtain the human platelet secretome (HPS) and ii) freezing and thawing platelet concentrates to obtain the most appropriate HPL. It is crucial to emphasize that our raw material will only be platelets that are currently discarded, due to expired storage time based on hemotherapy guidelines, but still retain full additional functionality. In addition to using this noble residue - which is submitted to several quality tests and tests negative for traditional pathogens traced in blood banks - we avoid the unfair competition with patients in the use of "fresh" concentrated platelets. Therefore, our company Plate(let) Form Biotechnology will be hosted in the Colsan blood bank (Benevolent Association for Blood Collection of the State of São Paulo) as an emerging startup and spin-off with the main objective of developing processes to convert expired platelets into a valuable product using simple, economical, environmentally friendly, and sustainable strategies. We know of the wide range of applications of our future product and the growing interest in the use of new cell supplementation products. We have the experience and ability to understand the needs of future customers and, therefore, we believe that the market is ready for platelet lysates and correlated products. An expanded business plan will be developed based on the outcomes of the initial period of activities. It is our intent to establish a successful presence in the Brazilian biotechnology market. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

FERREIRA-HALDER, CARMEN VERISSIMA; DE SOUSA FARIA, ALESSANDRA VALERIA; ANDRADE, SHEILA SIQUEIRA. Action and function of Faecalibacterium prausnitzii in health and disease. BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY, v. 31, n. 6, p. 643-648, DEC 2017. Web of Science Citations: 18.